Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

Willem Jan Fokkink; Annet Haarman; Anne Gillen; Wouter Rijs; Ruth Huizinga; Pieter van Doorn; B.C. Jacobs

doi:10.1002/acn3.307

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

Willem Jan Fokkink, Annet Haarman, Anne Gillen, Wouter Rijs, Ruth Huizinga, Pieter van Doorn, B.C. Jacobs

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

9 Downloads (Pure)

Abstract

Treatment of Guillain-Barre syndrome with a standard course of high-dose intravenous immunoglobulin ( IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.

Original language	Undefined/Unknown
Pages (from-to)	547-551
Number of pages	5
Journal	Annals of Clinical and Translational Neurology
Volume	3
Issue number	7
DOIs	https://doi.org/10.1002/acn3.307
Publication status	Published - 2016

Research programs

EMC MM-02-72-02
EMC MM-04-44-02

Access to Document

10.1002/acn3.307

REPUB_101581-OA.pdfFinal published version, 144 KB

Cite this

@article{e34fc0a3624641a7852b410c148be85f,

title = "Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS",

abstract = "Treatment of Guillain-Barre syndrome with a standard course of high-dose intravenous immunoglobulin ( IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.",

author = "Fokkink, {Willem Jan} and Annet Haarman and Anne Gillen and Wouter Rijs and Ruth Huizinga and {van Doorn}, Pieter and B.C. Jacobs",

year = "2016",

doi = "10.1002/acn3.307",

language = "Undefined/Unknown",

volume = "3",

pages = "547--551",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley & Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

AU - Fokkink, Willem Jan

AU - Haarman, Annet

AU - Gillen, Anne

AU - Rijs, Wouter

AU - Huizinga, Ruth

AU - van Doorn, Pieter

AU - Jacobs, B.C.

PY - 2016

Y1 - 2016

N2 - Treatment of Guillain-Barre syndrome with a standard course of high-dose intravenous immunoglobulin ( IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.

AB - Treatment of Guillain-Barre syndrome with a standard course of high-dose intravenous immunoglobulin ( IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barre syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.

U2 - 10.1002/acn3.307

DO - 10.1002/acn3.307

M3 - Article

C2 - 27386503

SN - 2328-9503

VL - 3

SP - 547

EP - 551

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 7

ER -